133 results match your criteria: "Harvard Medical School Department of Psychiatry[Affiliation]"
PLoS One
December 2024
Boston Children's Hospital (Department of Psychiatry and Behavioral Sciences), Boston, Massachusetts, United States of America.
Exposure to stressful events is linked to anxiety symptoms in children, although research examining this association in the first five years of life is limited. We sought to examine the role of various aspects of family stressful experiences such as the total accumulation, impact, and type (measured longitudinally in the first five years of life) on child anxiety symptoms at age 5 years. A community sample of children and their parents (N = 399) enrolled in a longitudinal study of emotion processing were assessed when the children were infants and at ages 2 years, 3 years, and 5 years.
View Article and Find Full Text PDFAm J Prev Med
November 2024
Cambridge Health Alliance Health Equity Research Lab, Cambridge, MA.
Learn Health Syst
June 2024
Cambridge Health Alliance Department of Psychiatry Cambridge Massachusetts USA.
Introduction: Behavioral measurement-based care (MBC) can improve patient outcomes and has also been advanced as a critical learning health system (LHS) tool for identifying and mitigating potential disparities in mental health treatment. However, little is known about the uptake of remote behavioral MBC in safety net settings, or possible disparities occurring in remote MBC implementation.
Methods: This study uses electronic health record data to study variation in completion rates at the clinic and patient level of a remote MBC symptom measure tool during the first 6 months of implementation at three adult outpatient psychiatry clinics in a safety net health system.
Bipolar Disord
September 2024
Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Schizophr Res Cogn
September 2024
University of Oxford, Oxford, UK.
Despite the functional impact of cognitive deficit in people with psychosis, objective cognitive assessment is not typically part of routine clinical care. This is partly due to the length of traditional assessments and the need for a highly trained administrator. Brief, automated computerised assessments could help to address this issue.
View Article and Find Full Text PDFPsychol Med
April 2024
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
The reading the mind in the eyes test (RMET) - which assesses the theory of mind component of social cognition - is often used to compare social cognition between patients with schizophrenia and healthy controls. There is, however, no systematic review integrating the results of these studies. We identified 198 studies published before July 2020 that administered RMET to patients with schizophrenia or healthy controls from three English-language and two Chinese-language databases.
View Article and Find Full Text PDFNeuropsychopharmacology
February 2024
McLean Hospital Schizophrenia and Bipolar Disorder Program, Belmont, MA, USA.
Schizophr Res
November 2023
Department of Psychiatry, Columbia University, New York, NY, USA.
Trials
October 2022
Department of Clinical Psychology, VU University and Amsterdam Public Health Research Institute, Room MF-B543, Van der Boechorstraat 7, Amsterdam, 1081 BT, the Netherlands.
Child Maltreat
February 2024
PediMIND Program, McLean Hospital, Division of Child and Adolescent Psychiatry, & Harvard Medical School Department of Psychiatry, Belmont, MA, USA.
Schizophr Res
October 2022
Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address:
Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC and the impact of cannabis use on APS, clinical status, and transition to psychosis.
View Article and Find Full Text PDFPsychol Med
July 2023
Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research, Manhasset, NY, USA.
Background: Psychiatric hospitalization is a major driver of cost in the treatment of schizophrenia. Here, we asked whether a technology-enhanced approach to relapse prevention could reduce days spent in a hospital after discharge.
Methods: The Improving Care and Reducing Cost (ICRC) study was a quasi-experimental clinical trial in outpatients with schizophrenia conducted between 26 February 2013 and 17 April 2015 at 10 different sites in the USA in an outpatient setting.
Nature
April 2022
MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Schizophr Res
May 2022
Department of Psychiatry, Columbia University, New York, NY, USA.
Multidimensional progressive declines in the absence of standard biomarkers for neurodegeneration are observed commonly in the development of schizophrenia, and are accepted as consistent with neurodevelopmental etiological hypotheses to explain the origins of the disorder. Far less accepted is the possibility that neurodegenerative processes are involved as well, or even that key dimensions of function, such as cognition and aspects of biological integrity, such as white matter function, decline in chronic schizophrenia beyond levels associated with normal aging. We propose that recent research germane to these issues warrants a current look at the question of neurodegeneration.
View Article and Find Full Text PDFPsychiatry Res
May 2022
Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address:
Having a first-degree relative with a psychotic disorder increases an individual's risk for developing psychosis to 10% compared to 1% in the general population. The impact of being at family high-risk for psychosis (FHR) has been examined in samples of youth who are at clinical high-risk for psychosis (CHR). The second North American Prodrome Longitudinal Study (NAPLS-2) identified very few clinical differences between CHR individuals with and without FHR.
View Article and Find Full Text PDFJ Contin Educ Health Prof
January 2022
Vinson: Assistant Professor, Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI. Iannuzzi: Psychiatric Social Worker, Brigham and Women's Hospital, Department of Psychiatry; Instructor, Harvard Medical School Department of Psychiatry, Boston MA. Bennett: Clinical Chair, Division of Developmental and Behavioral Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA. Butter: Chief & Associate Professor, Pediatrics, Psychiatry, & Psychology; Director, Child Development Center, Nationwide Children's Hospital, Ohio State University, Columbus, OH. Curran: Director of Strategic Initiatives, ECHO Autism; CDC's Act Early Ambassador in Missouri, Columbia, MO. Hess: Behavioral Health Outreach, Nationwide Children's Hospital, Columbus, OH. Hyman: Professor of Pediatrics, Division Chief, Developmental and Behavioral Pediatrics, University of Rochester, Rochester, NY. Kelly: National Director of Family Engagement, Devereux Advanced Behavioral Health, Philadelphia, PA. Murray: Vice President, Head of Clinical Programs, Autism Speaks, Adjunct Professor of Pediatrics, Department of Developmental & Behavioral Pediatrics, Cincinnati Children's Hospital Medical Center, College of Medicine, University of Cincinnati, Cincinnati, OH. Nowinski: Clinical Director of Non- Physician Services, Lurie Center for Autism, Massachusetts General Hospital, MA, and Instructor, Harvard Medical School, Boston, MA. Zwaigenbaum: Professor, Division of Developmental Pediatrics, Department of Pediatrics, University of Alberta, Edmonton, AB. Sohl: Professor, Department of Child Health, University of Missouri, Columbia, MO; Executive Director ECHO Autism.
Introduction: Project Extension for Community Healthcare Outcomes (ECHO) is used to increase provider capacity in a wide range of health care specialties. ECHO Autism: Center Engagement is a program that promotes improvement in autism care by improving the management of autism care centers. The program's focus brought experienced clinicians together as both facilitators and participants in an ECHO series.
View Article and Find Full Text PDFJ Clin Psychiatry
May 2021
Psychotic Disorders Division, McLean Hospital/Harvard Medical School Department of Psychiatry, Belmont, Massachusetts.
Psychol Med
March 2021
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, USA.
Background: Social cognition has not previously been assessed in treatment-naive patients with chronic schizophrenia, in patients over 60 years of age, or in patients with less than 5 years of schooling.
Methods: We revised a commonly used measure of social cognition, the Reading the Mind in the Eyes Test (RMET), by expanding the instructions, using both self-completion and interviewer-completion versions (for illiterate respondents), and classifying each test administration as 'successfully completed' or 'incomplete'. The revised instrument (RMET-CV-R) was administered to 233 treatment-naive patients with chronic schizophrenia (UT), 154 treated controls with chronic schizophrenia (TC), and 259 healthy controls (HC) from rural communities in China.
Psychol Med
February 2021
Institute of Psychology and Behavioral Science, Shanghai Jiao Tong University, Shanghai, PR China.
Background: Antipsychotics are widely used for treating patients with psychosis, and target threshold psychotic symptoms. Individuals at clinical high risk (CHR) for psychosis are characterized by subthreshold psychotic symptoms. It is currently unclear who might benefit from antipsychotic treatment.
View Article and Find Full Text PDFPsychiatry Res
February 2021
VA Boston Healthcare System, Boston MA and Harvard Medical School Department of Psychiatry, Boston MA. Electronic address:
Clozapine is vastly underutilized in the United States and many other countries. The most commonly cited reason for this is the requirement for frequent blood monitoring, which continues for the duration of treatment. Despite the notoriety clozapine achieved early in its development, accumulated evidence has demonstrated that close blood monitoring beyond the first year of treatment yields minimal safety benefits.
View Article and Find Full Text PDFEarly Interv Psychiatry
April 2021
McLean Hospital Schizophrenia and Bipolar Disorder Program, Harvard Medical School Department of Psychiatry, Belmont, Massachusetts, USA.
Aim: Cognitive remediation is an evidence-based intervention targeting the common and disabling cognitive deficits in people with psychosis. Findings from efficacy studies and meta-analyses show that cognitive remediation produces medium to large effects on cognition in both chronic and first episode patients. However, clinical availability of this treatment remains scarce, reflecting a major gap between science and practice.
View Article and Find Full Text PDFJ Stud Alcohol Drugs
March 2020
AdCare Hospital of Worcester, Worcester, Massachusetts.
Objective: The purpose of this study was to evaluate the costs and cost-effectiveness of two treatments for 101 alcohol use disorder patients and their intimate partners--group behavioral couples' therapy plus individual-based treatment (G-BCT), or standard behavioral couples' therapy plus individual-based treatment (S-BCT).
Method: We estimated the per-patient cost of each intervention using a microcosting approach that allowed us to estimate costs of specific components in each intervention as well as the overall total costs. Using simple means analysis and multiple regression models, we estimated the incremental effectiveness of G-BCT relative to S-BCT.
Schizophr Res
June 2020
Harvard Medical School Department of Psychiatry at Beth Israel Deaconess Medical Center, Boston, MA, United States.
Background: Comparing the course of antipsychotic-naïve psychosis in low- and middle-income countries (LMIC) may help to illuminate core pathophysiologies associated with this condition. Previous reviews-primarily from high-income countries (HIC)-identified cognitive deficits in antipsychotic-naïve, first-episode psychosis, but did not examine whether individuals with psychosis with longer duration of untreated psychosis (DUP > 5 years) were included, nor whether LMIC were broadly represented.
Method: A comprehensive search of PUBMED from January 2002-August 2018 identified 36 studies that compared cognitive functioning in antipsychotic-naïve individuals with psychosis (IWP) and healthy controls, 20 from HIC and 16 from LMIC.
Psychol Med
March 2021
Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
Background: Only 30% or fewer of individuals at clinical high risk (CHR) convert to full psychosis within 2 years. Efforts are thus underway to refine risk identification strategies to increase their predictive power. Our objective was to develop and validate the predictive accuracy and individualized risk components of a mobile app-based psychosis risk calculator (RC) in a CHR sample from the SHARP (ShangHai At Risk for Psychosis) program.
View Article and Find Full Text PDF